A routine blood test taken by millions in the U.S. each year to measure “bad” cholesterol is not the best measure to guide treatment and prevent heart attacks and strokes, suggests a new Northwestern Medicine study published in JAMA. The study found that another blood test called apolipoprotein B (apoB) outperformed LDL and non-HDL cholesterol in guiding cholesterol-lowering therapy, such as taking statins and other medications.
“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. health care payers,” said study lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine.
According to Kohli-Lynch, this is the first comprehensive study to show that using apoB testing to guide cholesterol-lowering treatment is cost-effective.









